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A B S T R A C T
Aging-related diseases can be triggered by multiple factors such as oxidative stress. Oxidative stress is an im-
balance between free radicals and antioxidants, so today, compounds capable of reducing or neutralizing free
radicals are being studied for a therapeutic use. Origanum vulgare L. is a traditional medicinal plant used for a
wide number of health problems due to its antimicrobial, carminative and antioxidant activities. However, when
administered orally, gastrointestinal digestion can modify some of therapeutical properties. To avoid this, two
different solid oral formulations have been designed for an O. vulgare extract evaluating their antioxidant be-
haviours in vitro and in vivo after a simulation of gastrointestinal digestion. The results showed that the divided
powder has a lower antioxidant activity both in vitro and in vivo than the encapsulated extract. The quantitative
difference of polyphenols found on HPLC-DAD (especially luteolin, apigenin and caffeic acid) may explain the
differences in pharmacological activity. Thus, we propose that the best form to administrate O. vulgare extracts to
maintain the antioxidant properties is the encapsulated form, that is, two capsules of 250mg of a hydroalcoholic
extract of O. vulgare with a minimum of 33 % of rosmarinic acid as a daily dose.
1. Introduction
Origanum vulgare L. has traditionally been used in food industry and
cooking as a condiment, but also as a digestive and circulatory stimu-
lant. The essential oil from this plant is also used in aromatherapy and
perfumery, including soaps. Some other traditional uses include the
preparation as an infusion to treat digestive disorders, headaches, sore
throats or colds due to the antispasmodic, calmative, carminative,
diaphoretic, expectorant, stomachic and tonic effects [1]. Additionally,
most of the components of O. vulgare have been shown to have an an-
tioxidant activity in vitro by reducing free radicals formation [2–5] and
their antioxidant and cytoprotective effects in vivo [6–8]. The accu-
mulation of free radicals in the body has been considered one of the
factors involved in the development of various diseases related to aging,
so the identification of compounds capable of reducing them are of
interest.
The route of administration of a drug plays an important role in its
pharmacological activity. In general, oral administration which is
widely used is preferred because of its comfort for the patient. In the
specific case of the medicinal plants, the particle size of the extracts can
be very heterogeneous and have several chemical compounds re-
sponsible for their action that can be modified by gastrointestinal di-
gestion (which involves enzymes and pH variation). For these reasons,
the pharmaceutical formulation for oral administration can be very
important in the pharmacokinetics and pharmacodynamics of these
products [9]. In the laboratory, it is possible to simulate the effects of
the gastrointestinal digestion process on the chemical structure of the
different components of the extracts using an in vitro model and then
analyze their final pharmacological activity both in vitro and in vivo.
Among the different in vitro methods to quantify antioxidant activity,
the analysis of the scavenging activity of DPPH% radical is the most
frequently used method [10]. On the other hand, Caenorhabditis elegans
is a good in vivo model widely used due to its simplicity, low price,
reproducibility and molecular similarity with humans [11]. There are
several assays already described to study the anti-aging and antioxidant
effect produced by a compound in this organism, one of them recently
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published by our group [12].
The aim of this report is to determine the antioxidant activity of two
different oral pharmaceutical forms of O. vulgare hydroalcoholic ex-
tracts using both in vivo and in vitro models, before and after an in vitro
simulation of the gastrointestinal digestion process.
The bioaccessibility, defined by the amount of compound available
for absorption, can be conditioned by several factors. Some of these
factors are very influenced by the chemical structure (glycosylation,
esterification and polymerisation) [13,14]. Pharmaceutical formulation
can be used to preserve the chemical structure that could be modified
along the digestive tract. Although sometimes this effect can be cir-
cumvented by the administration of pro-drugs [15], plant extracts are
made up of multiple compounds so pharmaceutical formulation is a
good physical solution to prevent their degradation. Thus, two simple
oral formulations were designed. The first one is a divided powder with
a previous lyophilization to improve the stability of its components.
This powder, mixed with water, is the simplest form for oral adminis-
trarion. The second one is a hard gelatine capsule that contains the
extract. The capsule acts as a physical protective barrier of the chemical
compounds responsible for pharmacological activity. We have eval-
uated the influence of both formulations on bioaccessibility and phar-
macological activity (both in vitro and in vivo) after a simulated process
of gastrointestinal digestion and we have also performed a chemical
characterization by HPLC-UV to determine the changes produced in the
composition of the plant extracts throughout the process. These data
will allow to choose the form with the best bioaccessibility.
2. Materials and methods
2.1. Plant material, extraction and pharmaceutical form preparation
Flowered aerial parts from Origanum vulgare L. were collected in
June 2017 in Santacara (Navarra, Spain). A voucher specimen
(PAMP21629) was deposited in the herbarium of the Department of
Environmental Biology at the School of Sciences, University of Navarra
(Pamplona, Spain) after its authentication by Dra. R. Y. Cavero.
The hydroalcoholic extract was prepared from flowered aerial-dried
parts (10 g) that were macerated at 4 °C in 250mL of ethanol-water 50
% v/v for 24 h and then filtered by gravity. Maceration process was
repeated four times to extract as many components as possible and then
concentrated using a rotary-evaporator. Finally, the dry hydroalcoholic
extract (final yield of 3:1) was lyophilised and stored at - 40 °C in a
freezer until use.
Then, we select two simple solid oral pharmaceutical forms for this
extract, divided powder and hard gelatine capsules. The divided
powder was composed by extract of O. vulgare (with at least 30 % of
rosmarinic acid) and antiaglomerant (silicon dioxide E551). A daily
dose of 500mg of this form dissolved in water once a day would pro-
vide a minimum of 170mg of rosmarinic acid. The gelatine capsule was
composed by extract of O. vulgare (with at least 30 % of rosmarinic
acid) and antiaglomerant (silicon dioxide E551) into a gelatine capsule
nº 2. A daily dose of 500mg of extract would consist of two capsules
once a day, which would also provide a minimum of 170mg of ros-
marinic acid.
Quality control assays were performed in a small scale in three re-
plicates as a control in the production for each oral preparation.
According to Pharmacopeia (Real Farmacopea Española, 5th Edition),
capsules should satisfy uniformity content (assay B, 2.9.6), uniformity
mass (2.9.5) and disintegration assay (2.9.1), whereas divided powder
only needs to satisfy uniformity content and mass content for single-
dose powder preparations.
2.2. In vitro gastrointestinal digestion process
The in vitro gastrointestinal digestion process was performed ac-
cording to Gayoso et al. (2018) with some modifications. Enzymatic
solutions were freshly prepared and kept on ice until use: α-amylase
(#A1031, Sigma-Aldrich Co., St. Louis, MO) 1.3mg/mL in 1mM CaCl2;
pepsin (#77161, Sigma-Aldrich Co., St. Louis, MO) 160mg/mL in 0.1M
HCl; bile (#B8631, Sigma-Aldrich Co., St. Louis, MO) 25mg/mL plus
0.1 g of pancreatin (#P7545, Sigma-Aldrich Co., St. Louis, MO) in 0.1M
NaHCO3. Daily dose of each pharmaceutical form (equivalent a 500mg
of extract) were mixed with 12.5 mL of water and the digestion process
was performed in 50-mL tubes rotating at 22 rpm inside an incubator at
37 °C (Fig. 1). The oral phase (2min) started after adding 125 μL of
amylase solution and adjusting to physiological pH 6.5 with 1M
NaHCO3. Then, 165 μL of pepsin solution were added at pH 2.5 with
3M HCl for the gastric step (2 h). Intestinal step (2 h) was simulated by
adding 1250 μL of pancreatin-bile solution and adjusting pH to 7.5 with
1M NaHCO3. After that, the intestinal mixture was centrifuged (at
51.070 g, 40min, 4 °C) and the supernatant (absorbable fraction) was
separated from the pellet (non-absorbable fraction). Finally, both
fractions were lyophilised (Cryodos50, Telstar, Barcelona, Spain). A
control with two empty capsules and a blank without plant extract were
treated under the same conditions.













Fig. 1. Diagram of the in vitro gastrointestinal digestion process with the three
main steps (bucal, gastric and intestinal). Final samples after centrifugation
were the intestinal absorbable fraction supernatant (supernatant after final
centrifugation) and the intestinal non-absorbable fraction (pellet after final
centrifugation).
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in which the final concentration is the concentration of the mixture
after digestion (taking into account the enzymes and the solutions
added to adjust pH in each step) and the initial concentration is the
concentration of the sample prepared before this process (40mg/mL).
The bioactivity, defined as the physiological response, was adjusted
taking into account this bioaccessibility of the pharmaceutical form by
applying the percentage obtained to the results of the antioxidant as-
says:










2.3. In vitro antioxidant activity assay
Antioxidant activity can be monitored using the scavenging effect of
radicals on DPPH% (#D9132, Sigma-Aldrich Co., St. Louis, MO). This
activity was firstly confirmed by using thin layer chromatography (TLC)
as a qualitative assay disposing 10 μL of hydroalcoholic extract (crude
extract) (10mg/mL) in a Silicagel 60 F254nm with plastic base
(#105554, Merck KGaA, Darmstadt, Germany) that were eluted with
ethyl acetate - acetic acid - formic acid - water (100:11:11:26) in a
chromatography chamber. After separation, the plate was sprayed with
a 0.4 mg/mL DPPH% solution to identify the antioxidant activity by
turning into yellow.
The scavenging activity of the extract before and after digestion of
the two formulations (capsule and powder) were also quantified using
rosmarinic acid (#536954, Sigma–Aldrich Co., St. Louis, MO) as posi-
tive control. Lyophilised samples (before and after digestion) were
dissolved in either water or ethanol - water (1:1 v/v) at 10 different
serial concentrations (1000−1.95 μg/mL) [18]. The reaction was
monitored every 15min for 90min, registering absorbance at 517 nm to











x(%) 1 100sample blank
control blank
In which Abssample is the absorbance at 517 nm of the reaction in
presence of sample (sample dilution+DPPH% solution), Absblank is the
absorbance of the blank for each sample dilution (sample
dilution+DPPH% solvent) and Abscontrol is the absorbance of control
reaction (sample solvent+DPPH% solution).
Values in each point were expressed as EC50, that is the con-
centration in which the 50 % of the free radical DPPH% is reduced.
2.4. In vivo antioxidant activity assay
In vivo antioxidant activity of the hydroalcoholic crude extract and
the two absorbable fractions obtained after the digestion process was
quantified using the method recently described in C. elegans [12]. For
both formulations, the absorbable fraction of rosmarinic acid was used
as positive control and as a reference besides the non-digested extract.
For the powder, we evaluated the blank with no extract as a negative
control to verify the absence of activity of the residual enzymes. For the
formulation in capsules, the lyophilised powder of the negative control
of two empty capsules was also analysed. For all the samples, six dif-
ferent concentrations were tested (50, 20, 10, 1, 0.1 and 0mg/mL) and
the EC50 value from the scavenging activity of DPPH% was plotted as
described [12] using GraphPad Prism v6.01 (GraphPad Software, La
Jolla, CA).
2.5. Chemical characterisation
O. vulgare hydroalcoholic extract chemical composition was firstly
qualitatively analysed by TLC, using the same stationary and mobile
phases suitable for flavonoids and phenolic compounds described
before [19]. Fractions obtained from the in vitro gastrointestinal process
were also analysed. Spots were observed at visible light, 254 nm and
366 nm. A better visualisation of the spots was obtained after treatment
with NP reagent (#126705, Sigma–Aldrich Co., St. Louis, MO) at
366 nm.
The main compounds of the extracts were quantitatively identified
by High Performance Liquid Chromatography with Diode Array
Detector (Waters HPLC 600E multi-solvent delivery system, a Waters
U6K sampler and a Waters 991 photodiode-array detector, Waters
Corp., Milford, MA). Samples were injected in a C18 reversed phase
column (Nova-Pak 150mm×3.9mm, 4 μm, Waters Corp., Milford,
MA) at 25 °C with a flow rate of 0.8mL/min and were eluted with
acetonitrile (#34851, Sigma–Aldrich Co., St. Louis, MO) (solution A)
and acidified water type I adjusted to pH 2 with formic acid (#33015,
Sigma–Aldrich Co., St. Louis, MO) (solution B), in different proportions
(%) of solution B: 0−10min, 95 %; 10−20min, 95−90 %;
20−35min, 90−80%; 35−45min, 80−60 %; 45−50min, 80−20 %
and then 95 % in 5min. The range of detection was established between
210 and 550 nm.
Results were used as a reference for the extract and compared with
the absorbable and non-absorbable fractions of the two formulations.
Identification of compounds was carried out according to literature and
the use of standard samples (caffeic acid -#C0625-, rosmarinic acid
-#R4033-, apigenin -#10,798-, luteolin -#L9283-, luteolin-7-O-gluco-
side -#1,370,837-, and 3,4-dihydroxybenzoic acid # 37,580 -, all from
Sigma–Aldrich Co., St. Louis, MO) at five different concentrations to
build a calibration curve. Thus, the areas under the curve (AUC) of the
main peaks were expressed in terms of mg of the standard compound
per 100 g of extract by linear regression analysis. The reproducibility of
the chromatographic separations was verified with a second HPLC
process [20]. All samples were injected in triplicate.
2.6. Statistical analysis
EC50 values were generated with GraphPad Prism, v6.01 (GraphPad
Software, La Jolla, CA). Means, standard deviations and graphs were
obtained with Microsoft Excel 2013 (Microsoft Corp., Redmond, WA).
Statistical analysis was performed using Stata v.12 (StataCorp LLC,
College Station, TX). Normality was checked by Shapiro-Wilkinson test.
Differences were estimated by ANOVA followed by pairwise compar-
ison post hoc test using Tukey’s method (99.9 % CL) or post-estimation
margins to check interaction among groups.
3. Results
3.1. Preparation of the pharmaceutical forms: quality control assays
The capsules must fulfil assay B of content uniformity (2.9.6) in the
mean±15 %. Our formulation met these requirements, being the total
mass 311.15 ± 0.94mg for individual full-filled capsule with a content
of 250.01 ± 0.64mg. The uniformity mass assay (2.9.5) accepts a 10
% of deviation for capsules with less than 300mg. This value in our
formulation was a 0.03 %. Divided powder preparations also met
content uniformity and mass assays, being their values in the range of
502.04 ± 0.06mg.
The disintegration of the capsules during the in vitro gastrointestinal
digestion process also satisfied the established conditions for capsules
and tablets (2.9.1) (i.e., capsules were disintegrated after 30min at
gastric conditions in a solution with HCl 0.1M or gastric enzymes).
Empty capsules, whose result for uniformity and mass assay was
61.14 ± 0.01mg/mL, also met such requirements.
3.2. In vitro gastrointestinal digestion process: bioaccessibility
The process of the in vitro gastrointestinal digestion involves the
addition of enzymes and a pH adjustment according to the physiology
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of the gastrointestinal tract at every stage. The effects of this process
depend on the nature of the initial sample. The bioaccessibility of the
two formulations (capsule and powder) was expressed as the percen-
tage of the final concentration with respect to the initial concentration
[12], being 87.17 % and 83.11 % for the encapsulated extract and the
powder respectively.
3.3. Antioxidant activity assays
Qualitative TLC assay with DPPH% showed that the two formulations
retained antioxidant activity after the gastrointestinal digestion pro-
cess. The purple DPPH% solution turns into yellow in presence of anti-
oxidants. Fig. 2 shows the results on TLC for the crude extract and both
the intestinal absorbable and non-absorbable fractions (pellets) from
the two formulations.
Antioxidant activity of the crude extract and the intestinal absorb-
able fractions from both formulations was then quantified also by
DPPH% method, recording values of absorbance at 517 nm every 15min
for 90min and calculating EC50 values in each time point (Fig. 3). The
activity of the non-absorbable fraction (pellet) was not quantified be-
cause this part will be excreted without being absorbed.
The reaction is stable when no statistical differences (p > 0.05) are
observed between two consecutive values. For the positive control, the
reaction with digested rosmarinic acid (RA) takes more time to stabilize
than the reaction with the non-digested RA (before digestion: p=
0.120 between EC50 at 15min and EC50 at 30min; after digestion: p=
0.991 between EC50 at 30min and EC50 at 45min). The extract ad-
ministrated as powder has a similar behaviour but delayed in time
(before digestion: p= 0.475 between EC50 at 30min and EC50 at
45min; after digestion: p=0.999 between EC50 at 45min and EC50 at
60min). However, the reaction of the extract encapsulated after di-
gestion stabilizes at the same time as the non-digested extract (p=
0.945 between EC50 at 30min and EC50 at 45min).
Rosmarinic acid showed no statistical differences in scavenging
activity before and after digestion in vitro at the time of stability of the
reaction: EC50,15 min= 1.71 ± 0.04 μg/mL and EC50,
30 min= 1.88 ± 0.15 μg/mL, respectively with p= 0.999. However,
the pharmaceutical form has influence in the antioxidant activity of the
hydroalcoholic extract. The encapsulated hydroalcoholic extract
showed no statistical differences before and after digestion at the time
of stability: EC50, 30min=4.06 ± 0.39 μg/mL and EC50,
30min=3.77 ± 0.30 μg/mL, respectively with p= 0.981. By con-
trast, scavenging activity after digestion of the extract administrated as
powder was significantly increased, which means a lower antioxidant
activity (p= 0.001, EC50, 45min=4.86 ± 0.58 μg/mL). In fact, both
formulations show different antioxidant activities in vitro (p < 0.001).
The antioxidant activities of the samples and the positive control
were statistical different at all time-points (p < 0.001). As expected,
empty capsules digested (used as blank for encapsulated extract) and
the Blank sample (digestion without sample) did not show any anti-
oxidant activity in vitro. For further information, scavenging activity (as
% inhibition) is compiled in supplementary table S1.
The antioxidant activity of the different extracts was also monitored
in vivo after C. elegans treatment every 15min for 90min. Results ex-
pressed in EC50 were represented also as a function of time (Fig. 4). In
this case, rosmarinic acid reached stabilisation of the reaction earlier
when the sample had previously been digested in vitro (before digestion:
p= 0.695 between min 60 and 75; after digestion: p= 0.631 between
min 45 and 60). Like the results obtained with in vitro assays, the extract
showed a different behaviour in stabilisation depending on the phar-
maceutical form. The extract administrated as a powder showed similar
results to rosmarinic acid, reaching a stabilization earlier than the crude
extract (before digestion: p= 0.343 between min 45 and 60; after di-
gestion: p= 0.825 between min 30 and 45). In contrast, encapsulated
extract required the same time as the non-digested extract to reach the
stabilization time point (p= 0.912 between min 45 and 60).
After stabilization of the reaction, rosmarinic acid showed no sta-
tistical differences (p= 0.054) between the in vitro digested sample
(RAInt) and the pure compound (RA) (EC50, 60min=8.50 ± 0.33 μg/
mL and EC50, 45 min= 8.49 ± 0.59 μg/mL respectively).
Again, scavenging activity of the hydroalcoholic extract seems to
depend on the pharmaceutical form in which the gastrointestinal di-
gestion was performed. Intestinal absorbable fraction of the extract as
powder showed a lower activity (p < 0.001) in vivo than the en-
capsulate form at the stabilization point (EC50,
30min=30.71 ± 2.50 μg/mL and EC50, 45min=21.14 ± 1.60 μg/
mL, respectively). When compared to the in vivo antioxidant activity of
the crude extract, the powder form showed no differences (p= 0.209,
EC50, 45min=28.74 ± 0.58 μg/mL before digestion and EC50,
30min=30.71 ± 2.50 μg/mL after digestion) but the encapsulated
form showed differences with both of them (p < 0.001).
Furthermore, there were statistical differences between the samples
and the positive control (p < 0.001). As expected, empty capsules
digested (used as blank for encapsulated extract) and the Blank sample
(digestion without sample) did not show any antioxidant activity in
vivo. For further information, scavenging activity (% inhibition) is
compiled in supplementary table S2.
Therefor, the results of in vitro and in vivo assays to quantify the
antioxidant activity pointed that the encapsulated extract shows a
higher antioxidant activity than the powder form after the digestion
process, but this activity is also greater than the activity of the crude
(non-digested) extract (Fig. 5). By contrast, rosmarinic acid used as
positive control of antioxidant activity seems to maintain this activity in
the in vitro and in vivo assays after the digestion process.
3.4. Chemical characterisation
Chemical characterisation of the samples before and after gastro-
intestinal digestion in vitro was performed qualitatively (TLC) and
quantitatively (HPLC-UV).
TLC did not show important differences between the two formula-
tions (Fig. 6A). Exposition to NP reagent allowed the identification by
colour of the main compounds in the hydroalcoholic extract. Blue is
characteristic of phenolic acids (1, 6) and hydroxybenzoic acids (3, 7);
yellow-orange is characteristic of flavonoids (2, 4, 5) (Fig. 6A) [19].
Crude hydroalcoholic extract was characterised by HPLC-UV at
Fig. 2. Qualitative antioxidant assay on TLC. (A) OV-E: non-digested hi-
droalcoholic extract (crude extract). (B) OV-P: extract in powder after gastro-
intestinal digestion. (C) OV-C: extract in capsules after digestion. Int.: intestinal
absorbable fraction; Pellet: intestinal non-absorbable fraction.
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325 nm, allowing identification of the seven main compounds by re-
tention time and UV spectrum using standards with the same conditions
(Fig. 6B). The AUC of each peak obtained from chromatograms was
transformed into concentration by linear regression analysis using
known concentrations of the standards to build calibration curves.
These standards were caffeic acid (= −x158,084,586.42 137,425.76 ; R2
= 0.9998), rosmarinic acid ( = +y x38,442,146.87 88,581.28; R2 =
1.0000), apigenin ( = −y x301,259,751.23 65,541.33; R2 = 0.9998), lu-
teolin ( = +y x117,803,660.17 465,907.16; R2 = 0.9999) and 3, 4-DHBA
( = −y x435,588,549.58 57,118.73; R2 = 0.9988).
The amount of the identified compounds was compared among the
different samples and expressed in mg of standard per 100 g of sample
(Table 1).
As expected, the main compound detected in the hydroalcoholic
extract is rosmarinic acid (peak 6; 34.10 ± 0.04mg in the crude ex-
tract) even after the process of digestion for both pharmaceutical forms.
This compound has a bioaccessibility of 55.13 % (capsule) and 53.66 %
(powder) after digestion. 3,4-dihydroxybenzoic acid (3,4-DHBA; peak
Fig. 3. Temporal evolution of antioxidant ac-
tivity in vitro (the DPPH% method) expressed in
EC50 (mean ± SD μg/mL). Continuous lines in
the graph correspond to data from non-di-
gested samples and spotted lines to intestinal
absorbable samples after digestion. Data for
the positive control (rosmarinic acid, RA) are
showed in dark grey; green line represents the
crude extract (OV-E); dashed orange line re-
presents the intestinal fraction of the two cap-
sules digested (OV-C) and dashed blue line the
divided powder after the digestion process
(OV-P). The antioxidant activities of the ex-
tracts and RA showed differences at all time-
points (p < 0.001). Table below the graph
shows the EC50 mean values (SD) expressed in
μg/mL. Bold values indicate the time points in
which no differences (p > 0.05) with their
consecutive value could be observed. a and b
indicate no differences (p > 0.05) among the
values compared at stabilisation time, whereas
c and d indicate that those values show statis-
tical differences (p < 0.05).
Fig. 4. Temporal evolution of antioxidant ac-
tivity in vivo (DPPH% method) expressed in
EC50 (mean ± SD μg/mL). Continuous lines in
the graph correspond to data from non-di-
gested samples and spotted lines to intestinal
absorbable samples after digestion. Data for
the positive control (rosmarinic acid, RA) are
showed in dark grey; green line represents the
crude extract (OV-E); dashed orange line re-
presents the intestinal fraction of the two cap-
sules digested (OV-C) and dashed blue line the
divided powder after the digestion process
(OV-P). Antioxidant activities of the extracts
and RA showed differences in all time-points
(p < 0.001). Table below the graph shows the
EC50 mean values (SD) expressed in μg/mL.
Bold values indicate the time points in which
no statistical differences (p > 0.05) with their
consecutive value could be observed. a and b
indicate no statistical differences (p > 0.05)
among the values compared at stabilisation
time, whereas c and d indicate that those values
are statistically differences (p < 0.05).
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3, 18.04 ± 0.11mg in the crude extract) is another phenolic acid de-
tected. In this case the bioaccessibility was higher in the powder form
(65.85 %) than in the encapsulated form (59.64 %). Luteolin glycoside
(peak 4) and the apigenin glycoside (peak 5) are less abundant in the
crude extract and their bioaccessibility also depends on the pharma-
ceutical form (83.31 % and 89.28 % for the encapsulated form and
55.79 % and 54.16 %, respectively, for the powder). The bioaccessi-
bility of caffeic acid (peak 1) is also higher for the encapsulated extract
(87.16 % and 77.00 %, for the encapsulated form and powder respec-
tively). The first flavonoid that appears in the chromatogram (luteolin
glycoside, peak 2) is potentially bioaccesible in both forms (82.52 % for
the encapsulated form and 80.99 % for the powder). Finally, the
compound corresponding to peak 7 seems to be a derivate of 3,4-DHBA
and it shows a low bioaccessibility in both forms (32.55 % and 24.56 %
for the encapsulated form and powder respectively).
In general, both formulations seem to release in the intestine similar
but low quantities of phenolic acids (56.79 % for capsules and 54.87 %
for powder) and DHBA (43.55 % for capsule and 42.46 % for powder).
However, in the case of the flavonoids, quantities depend largely on the
formulation (84.96 % for encapsulated form and 63.48 % for powder).
4. Discussion
The pathologies related to aging seem to be related with the un-
balance of reactive oxygen species (ROS). The gastrointestinal tract
involves ROS as essential signalling intermediates for the maintenance
of homeostasis [25] and compounds either able to reduce the un-
necessary generation of ROS or neutralize them could be potentially
oral treatments to prevent and restore a normal balance. In antioxidant
therapies based on herbal preparations, some natural extracts show this
activity in vitro but lose efficacy when they are tested in vivo [26]. This
fact may be due to the lack of information on the pharmacokinetics and
pharmacodynamics of these extracts [9] but also there are many factors
that may influence the stability of their chemical composition. On one
hand, it is evident from many studies that the choice of the solvent has a
large impact on the stability of the extracts [27,28]. The best stability is
acquired when the solvent is ethanol, followed by methanol and DMSO.
In fact, the importance of water in the instability of extracts has been
largely demonstrated. Water causes redox reactions and the formation
of hydroxyl radicals and hydrogen peroxide with oxidative properties.
Water also promotes enzymatic reactions, which are especially un-
favourable for the extracts in liquid form [29]. Physicochemical prop-
erties of the solvents (and temperature) can also affect the chemical
composition of the extract and its pharmacological activity [30,31].
Generally, organic solvents tend to extract a greater amount of poly-
phenols, which are primarily responsible for the antioxidant activity
[32]. We chose for this work lyophilized 50 % ethanolic cold extract of
O. vulgare titrated at 33 % of rosmarinic acid.
The pharmacological actions of O. vulgare might be related by its
antioxidant activity [1]. For this reason, we have tested the antioxidant
activity of an O. vulgare extract both in vitro and in vivo before and after
an in vitro gastrointestinal digestion process. The interest of this study is
that this plant is widely used orally and in this way we could evaluate
the effect of gastrointestinal enzymes and the acidity of the stomach on
this activity, as this may constitute a key barrier to its effectiveness after
oral administration. Moreover, water-based oral medications show a
risk of microbiological contamination, may limit the solubility of some
important compounds and may require the addition of some excipients
that increase costs to achieve agreeable organoleptic characteristics. All
this makes liquid oral forms comparatively more expensive, with
practical and safety complications in their storage due to their low
transportability, large volumes and fragile containers [33,34]. Alter-
natively, solid oral dosage forms supplement all these disadvantages
with greater pharmaceutical and chemical stability, dosing accuracy,
better transportability and ease of storage [35].
Among solid oral single-dose pharmaceutical preparations, we have
opted for gelatine capsules and divided powder. Encapsulation was
chosen due to the simplicity of the preparation of this form that, a priori,
does not produce any alteration in the bioactive chemical compounds of
the extract. Gelatine is a gelling protein widely applied in the food and
Fig. 5. Antioxidant activity quantified by the DPPH% method from the in vitro
(left) and in vivo (right) assays expressed in EC50 (mean and error bars in μg/
mL). Values at stabilization point. Black coloured bars represent the crude ex-
tract (OV-E); grey bars, the intestinal fraction of the two capsules digested (OV-
C) and light grey bars, the powder after digestion process (OV-P). The lower the
bar, the more antioxidant the sample is. *** indicates statistical differences
between series (p < 0.001).
Fig. 6. (A) Thin layer chromatography (TLC)
of the two formulations before and after the
process of in vitro gastrointestinal digestion
revealed with NP solution and observed at
366 nm. Left: TLC results corresponding to
lyophilised powder. Right: TLC results corre-
sponding to encapsulated extract. In both
cases: crude extract corresponds to results of
the non-digested hydroalcoholic extract;
Intestinal corresponds to the intestinal fraction
after digestion and Pellet corresponds to the
non-absorbable fraction after digestion. Colour
of each compound corresponds to the colour
observed on TLC with NP reagent: blue for
phenolic acids, green for hydroxybenzoic acid
and yellow-orange for flavonoids. The numbers correspond to the number of the peaks identified on HPLC. (B): HPLC chromatogram at 325 nm of the hydroalcoholic
extract before digestion. Main compounds are highlighted with their UV-spectra.
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pharmaceutical industries. Hard gelatine capsules are easy to swallow,
odourless and tasteless, so they mask the unpleasant taste of products.
However, sometimes they have some hygroscopic problems (the cap-
sules contain around 12 % water) so we added silicon dioxide as anti-
aglomerant to facilitate its industrial production, drug release and di-
gestion. As for its size, they are only physical containers and the small
capsules limit their content and the large ones are difficult to swallow
so we choose number 2 with a capacity of 0.36mL.
The second formulation was powder, which is not physically limited
in dosage. The powder can be presented as a unidose (divided powder)
or multidose (bulk powder). Unidose powder preparations are ready-to-
take whereas the bulk powders may need a dispenser device (like a
measuring spoon). Regardless of the packaging, the powder consists of
solid, loose and dry particles designed to be resuspended in water
avoiding the inconvenience of swallowing for some patients with pro-
blems of this type. On the other hand, depending on the type of com-
pound this formulation may need coloring and / or flavoring sub-
stances. Thus, like capsules, it can contain one or more active
ingredients, with or without excipients. In this case we selected silicon
dioxide for the same reasons as before.
Despite the fact that O. vulgare is widely used in traditional medi-
cine, there is no a formal monography that compiles recommendations
for therapeutic doses. European Medicine Agency (EMA) has two
published monographies for two close subspecies: O. majorana and O.
dictamnus. Our hydroalcoholic extract showed a yield of 28.48 %, which
means that 1.13 g of extract is comparable to 4 g of dried plant.
According to EMA indications, daily dose for O. majorana is between 2
and 4 g of dried plant, once or twice after meals [36]. Thus, as an or-
ientation for a therapeutic dose of O. vulgare we selected the lowest
daily dose, that is, 509mg of extract. According to the size capsule
chart, the capsules number 2 (with 0.36mL of capacity) admit up to
250mg of extract and 0.1mg of excipient. Therefore, two capsules or
500mg of the divided powder could be considered as the daily dose.
Uniformity and mass content assays were performed for all samples
according to the Pharmacopeia (Real Farmacopea Española 5th ed.,
2006, [37]), being 61.14 ± 0.34mg for individual empty capsules
(122.29 ± 0.18mg for daily dose), 311.15 ± 0.94mg for individual
full-filled capsules (with a content of 250.01 ± 0.64mg) and
502.04 ± 0.06mg for the powder. Besides, the disintegration assay for
the capsules (empty and fulfilled) was provided by the in vitro gastro-
intestinal digestion process. The powder showed solubility in water at
40mg/mL, so the daily dose can be easily administered dissolved in a
glass of water. Both formulations showed chemical ex corpore char-
acteristics suitable to be administered in an in vivo model.
Drug release is the first crucial step in pharmacokinetics (LADME
system) in which small differences could explain variations in the
pharmacological activity of the preparation. As shown (Fig. 2), the
antioxidant activity in vitro of the extract depends on the formulation.
Encapsulated extract is able to maintain this activity after an in vitro
gastrointestinal digestion process, assuming that the capsule protects
the extract (with an EC50, 30min=4.06 ± 0.39 μg/mL before diges-
tion and an EC50, 30min= 3.77 ± 0.30 μg/mL after digestion; p=
0.981). Thus, the capsule could preserve the activity by protecting the
compounds that, in the case of dry powder, are directly exposed to
stomach acidity and enzymes (pepsin) (EC50, 45min=4.86 ±
0.58 μg/mL, p < 0.001). On the other hand, the capsule disintegra-
tion itself seems to make the extract reach its maximum activity 15 min
later than the powder or rosmarinic acid. Finally, the encapsulated
extract achieves stability in its activity in a similar manner to the non-
digested sample (at min 30), perhaps due to less chemical and struc-
tural damage suffered by its components. Empty-digested capsules
showed a baseline scavenging activity, so they did not show antioxidant
activity (supplementary table S1).
The total bioaccessibility was similar for both formulations, being
87.17 % for the capsules and 83.11 % for the powder. Metabolism and
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phenolic compounds (basic structure, molecular size, degree of poly-
merization or glycosylation, solubility and conjugation with other
phenolic compounds) [16]. HPLC-UV analysis (Table 2) helped us to
check the evolution of the compounds in the extract after the digestion
process. Phenolic acids seem to be affected by this process because their
total amount for intestinal absorption was around 50 % for both for-
mulations. Nevertheless, the capsules seem to have protected flavonoids
more, since their bioaccessibility was 84.96 % for the encapsulated
form and 63.48 % for the powder. The two flavonoids (apigenin gly-
coside and luteolin glycoside) and caffeic acid, all of them known an-
tioxidants, were significantly less present in the intestinal fraction of
the powder and could be the compounds that explain the different
bioactivities of both formulations. These compounds were also found in
the non-absorbable fraction of both formulations, explaining the yellow
spots of the qualitative antioxidant assay by TLC (Fig. 2). The bioac-
cesibilities of four of the seven identified compounds were not for-
mulation-dependent and they were minimally found in pellets (in-
testinal non-absorbable fractions).
Nonetheless, both formulations were shown to have potential anti-
oxidant activity in vitro due to the chemical stability of the components
of the extracts. For example, bioaccessibility of rosmarinic acid (con-
sidered the primary constituent in both formulations) was 55.1 % in the
capsule but also 53.6 % in the powder. In fact, we used rosmarinic acid
as positive control as it maintained its antioxidant activity in vitro be-
fore and after digestion when administered as a powder.
C. elegans is a simple in vivo model widely used for in vivo screenings
and functional analyses. Although antioxidant activity in this organism
can be assayed by quantifying in parallel the protein and gene ex-
pression [38] we have used a simple and reliable method recently de-
veloped [12] to quantify the internal antioxidant activity. With this
assay, we have verified that the antioxidant activity of the different
samples previously analysed in vitro is preserved in this organism. Thus,
rosmarinic acid (the main component of the O. vulgare extracts) also
behaves as antioxidant before and after the digestion process (EC50,
60 min= 8.50 ± 0.33 μg/mL and EC50, 45min=8.49 ± 0.59 μg/
mL; p= 0.054, respectively). As expected, in worms, the encapsulated
extract showed also a higher antioxidant activity than the powder
(EC50, 45min=21.14 ± 1.60 μg/mL and EC50, 30 min= 30.71 ±
2.50 μg/mL, respectively with p < 0.001), probably due to the var-
iation in the amount of flavonoids [39]. In fact, the non-digested extract
showed also a higher antioxidant activity in vivo. However, and sur-
prisingly, the digested encapsulated extract is more antioxidant than
the pure non-digested extract (Fig. 5). In addition, there is an analogy
between the results obtained in the in vitro and in vivo assays although
the differences are increased in the in vivo assays.
The crude extract was not digested, so we expected a similar be-
haviour to that of the encapsulated extract. When we analysed the
antioxidant activity in vitro, the crude extract showed maximum ac-
tivity but in vivo assays require exposure of the sample to the physio-
logical conditions of the worm. For example, although empty capsules
did not show antioxidant activity in vitro, their activity in vivo increased
up to 39.15 ± 9.00 % displaying a similar behaviour to glucose [12].
Thus, the baseline data obtained in the in vivo assays could be asso-
ciated to antioxidative pathways activated in the worms [40].
The quantification of antioxidant activity over time allows the
analysis of its stability. The reaction is fast when stability (maximum
activity) is reached before 30min, it is intermediate when it is reached
between 30 and 45min, and it is slow when it is reached after 60min.
Thus, rosmarinic acid after digestion is an intermediate antioxidant
both in vitro and in vivo (Figs. 3 and 4, in vitro ≥ 30min and in vivo ≥
45min), while before digestion, it is a fast antioxidant in vitro and a
slow antioxidant in vivo (the maximum points of antioxidant activity
were at 15 and 60min, respectively). Establishing the crude non-di-
gested extract as the control for the kinetic analyses, the digested
powder behaves similarly to rosmarinic acid reaching a stable time
point 15min later in vitro and 15min earlier in vivo. On the contrary,
the encapsulated form behaves similarly to the digested rosmarinic acid
reaching stability after 30min in vitro and after 45min in vivo.
In any case, according to the kinetic classification, there are no
differences between samples. The hydroalcoholic extract is an inter-
mediate antioxidant before and after digestion both in vitro and in vivo
for the two formulations. In this sense, the stability of the reaction does
not have an important role in the differences observed between the
digested powder and the encapsulated extract. However, the en-
capsulated form always shows a higher activity, so we consider that it
could be the optimal oral formulation for O. vulgare hydroalcoholic
extracts.
5. Conclusions
In conclusion, the oral pharmaceutical form may have an important
role in the pharmacological activity also for medicinal plant extracts.
Compared to powder, the encapsulation can protect physically the
components of the extracts from the digestion process, favouring the
maintenance of their antioxidant activity. Thus, two capsules of 250mg
of a hydroalcoholic extract of O. vulgare (with a minimum of 33 % of
rosmarinic acid) could be a potentially minimum daily dose for anti-
oxidant oral treatment.
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